Finance

Lists
CSTL:NASDAQ
Castle Biosciences Inc
$29.03
-3.07%
(-0.92) 1D
$29.03
0.00% (0.00)
After hours
Closed: Aug 18, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CSTL...
Open
$29.89
High
$30.12
Low
$28.72
Mkt. cap
886.85M
Avg. vol.
429.04K
Volume
596.61K
52-wk high
$44.28
52-wk low
$17.72
EPS
-$0.65
Beta
0.99
Shares outstanding
30.55M
No. of employees
1K
Open
$29.89
High
$30.12
Low
$28.72
Mkt. cap
886.85M
Avg. vol.
429.04K
Volume
596.61K
52-wk high
$44.28
52-wk low
$17.72
EPS
-$0.65
Beta
0.99
Shares outstanding
30.55M
No. of employees
1K
News stories
From web sources and news partners
About Castle Biosciences Inc
CEO-
Employees1K
Founded2007
HeadquartersFriendswood, Texas, United States
SectorHealth care provider
Websitecastlebiosciences.com
Analyst ratings
Based on 6 analysts giving stock ratings to CSTL in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for CSTL in the last 3 months.
Highest
Current $29.03
$57.00 (+96.35%)
Average
$42.00 (+44.68%)
Lowest
$35.00 (+20.56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kyle Mikson CFA
Canaccord Genuity
Buy
Maintained
$40.00
+37.8%
08/02/2026
Mark Massaro
BTIG
Buy
Reiterated
$44.00
+51.6%
08/03/2026
Max Masucci
Roth MKM
Buy
Maintained
$40.00
+37.8%
07/31/2026
Thomas Flaten
Lake Street
Buy
Maintained
$57.00
+96.3%
07/31/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$36.00
+24%
07/31/2026
Unknown Analyst
Roth MKM
Buy
Initiated
$40.00
+37.8%
06/24/2026
Paul Knight
KeyBanc
Buy
Maintained
$35.00
+20.6%
05/29/2026
Subbu Nambi
Guggenheim
Buy
Maintained
$47.00
+61.9%
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
83.04M
87.01M
83.68M
103.55M
Cost of goods sold
18.70M
18.32M
20.53M
23.70M
Cost of revenue
18.70M
18.32M
20.53M
23.70M
Research and development expenses
12.96M
13.52M
14.43M
14.54M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
55.91M
56.73M
64.90M
66.12M
Operating expense
71.14M
72.52M
81.55M
82.92M
Total operating expenses
89.85M
90.84M
102.09M
106.62M
Operating income
-6.80M
-3.83M
-18.41M
-3.07M
Other non operating income
48.00K
-48.00K
-439.00K
-153.00K
EBT including unusual items
-386.00K
-2.71M
-14.41M
-1.69M
EBT excluding unusual items
-3.95M
-859.00K
-16.44M
-1.06M
Income tax expense
115.00K
-382.00K
109.00K
370.00K
Effective tax rate
-29.79%
14.08%
-0.76%
-21.89%
Other operating expenses
-
-
-
-
Net income
-501.00K
-2.33M
-14.52M
-2.06M
Net profit margin
-0.60%
-2.68%
-17.35%
-1.99%
Earnings per share
-0.02
-0.08
-0.49
-0.07
Interest and investment income
2.83M
2.90M
2.54M
2.36M
Interest expense
-24.00K
-24.00K
-134.00K
-193.00K
Net interest expenses
2.81M
2.87M
2.41M
2.16M
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.17M
-50.00K
-14.48M
1.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps